CO2020014729A2 - Gene therapy constructs and methods for their use - Google Patents

Gene therapy constructs and methods for their use

Info

Publication number
CO2020014729A2
CO2020014729A2 CONC2020/0014729A CO2020014729A CO2020014729A2 CO 2020014729 A2 CO2020014729 A2 CO 2020014729A2 CO 2020014729 A CO2020014729 A CO 2020014729A CO 2020014729 A2 CO2020014729 A2 CO 2020014729A2
Authority
CO
Colombia
Prior art keywords
methods
gene therapy
therapy constructs
constructs
therapeutic protein
Prior art date
Application number
CONC2020/0014729A
Other languages
Spanish (es)
Inventor
Russell Gotschall
Hung Do
Steven Tuske
Ce Feng Liu
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CO2020014729A2 publication Critical patent/CO2020014729A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/02Thioester hydrolases (3.1.2)
    • C12Y301/02022Palmitoyl-protein hydrolase (3.1.2.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105Alpha-N-acetylglucosaminidase (3.2.1.50)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/10Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente vectores mejorados para terapia génica y métodos de uso. En algunas formas de realización, que comprenden secuencias para la expresión mejorada y la selección celular de una proteína terapéutica.Improved vectors for gene therapy and methods of use are provided herein. In some embodiments, they comprise sequences for enhanced expression and cellular selection of a therapeutic protein.

CONC2020/0014729A 2018-04-30 2020-11-27 Gene therapy constructs and methods for their use CO2020014729A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862664741P 2018-04-30 2018-04-30
US201862688640P 2018-06-22 2018-06-22
US201862744068P 2018-10-10 2018-10-10
PCT/US2019/030076 WO2019213180A1 (en) 2018-04-30 2019-04-30 Gene therapy constructs and methods of use

Publications (1)

Publication Number Publication Date
CO2020014729A2 true CO2020014729A2 (en) 2020-12-21

Family

ID=66669057

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0014729A CO2020014729A2 (en) 2018-04-30 2020-11-27 Gene therapy constructs and methods for their use

Country Status (16)

Country Link
US (3) US10874750B2 (en)
EP (1) EP3788064A1 (en)
JP (2) JP2021521851A (en)
KR (1) KR20210005154A (en)
CN (1) CN112513071A (en)
AU (1) AU2019261982A1 (en)
BR (1) BR112020021962A2 (en)
CA (1) CA3098674A1 (en)
CL (1) CL2020002809A1 (en)
CO (1) CO2020014729A2 (en)
MX (1) MX2020011514A (en)
PH (1) PH12020551818A1 (en)
SG (1) SG11202010533WA (en)
TW (2) TWI808169B (en)
WO (1) WO2019213180A1 (en)
ZA (1) ZA202006905B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098674A1 (en) * 2018-04-30 2019-11-07 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
WO2021072372A1 (en) * 2019-10-10 2021-04-15 Amicus Therapeutics, Inc. Variant igf2 constructs
IL293068A (en) * 2019-11-19 2022-07-01 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
CA3177954A1 (en) * 2020-05-14 2021-11-18 James M. Wilson Compositions useful for treatment of pompe disease
WO2022026410A2 (en) 2020-07-27 2022-02-03 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
CN117120619A (en) 2020-07-27 2023-11-24 沃雅戈治疗公司 Compositions and methods for treating neurological disorders associated with a deficiency in glucosylceramidase beta
WO2022104186A1 (en) * 2020-11-16 2022-05-19 Tavotek Biotherapeutics (Hong Kong) Limited A shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
JP2023551911A (en) 2020-12-01 2023-12-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and uses thereof for the treatment of Angelman syndrome
WO2023086939A1 (en) * 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia
EP4433490A2 (en) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024151982A1 (en) 2023-01-13 2024-07-18 Amicus Therapeutics, Inc. Gene therapy constructs for the treatment of pompe disease
WO2024163012A1 (en) 2023-02-02 2024-08-08 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1118334A1 (en) 2000-01-11 2001-07-25 Aventis Behring Gesellschaft mit beschränkter Haftung Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
WO2003032727A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
DE10237639A1 (en) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Preparing virus-like particles, useful as gene therapy vectors, comprises assembling capsomers, optionally with active molecules attached, in presence of nonionic stabilizers
JP5433133B2 (en) 2003-01-22 2014-03-05 デューク・ユニヴァーシティ Improved construct for expressing lysosomal polypeptides
WO2004098648A1 (en) * 2003-05-01 2004-11-18 Genzyme Corporation Gene therapy for neurometabolic disorders
GB0314856D0 (en) * 2003-06-25 2003-07-30 Unitargeting Res As Protein expression system
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
ATE465250T1 (en) 2004-02-10 2010-05-15 Zystor Therapeutics Inc ACID ALPHA-GLUCOSIDASE AND FRAGMENTS THEREOF
ES2242542B1 (en) * 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas PROCEDURE FOR THE PRODUCTION IN LEAVES OF EMPTY VIRAL CAPSIDES COMPOSED BY PROTEINS DERIVED FROM PVP2 OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV).
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
CN1903374A (en) * 2005-07-27 2007-01-31 中国人民解放军军事医学科学院生物医学分析中心 Application of colon bacillus for preparing medicine for diagnosis and treatment of tumor
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
EP2279210B1 (en) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
PL3903829T3 (en) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
ES2687415T3 (en) 2010-11-22 2018-10-25 Amicus Therapeutics, Inc. New signal sequences to improve protein expressions and the secretion of recombinant enzymes and other proteins
PL2646044T3 (en) * 2010-11-30 2020-03-31 Orphazyme A/S Methods for increasing intracellular activity of hsp70
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
JP5992902B2 (en) 2011-03-16 2016-09-14 天野エンザイム株式会社 Modified α-glucosidase and use thereof
CN108586621A (en) 2011-05-27 2018-09-28 阿米库斯治疗学公司 Targeting peptides are coupled to the method on recombination lysosomal enzyme
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
PL3115372T3 (en) 2012-11-27 2019-09-30 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
WO2014143701A1 (en) * 2013-03-15 2014-09-18 Amicus Therapeutics, Inc. Chemical crosslinkers
US20160243260A1 (en) 2013-10-24 2016-08-25 Uniqure Ip B.V. Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
CA3098674A1 (en) 2018-04-30 2019-11-07 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use

Also Published As

Publication number Publication date
EP3788064A1 (en) 2021-03-10
CN112513071A (en) 2021-03-16
US11491243B2 (en) 2022-11-08
ZA202006905B (en) 2022-03-30
JP2024119788A (en) 2024-09-03
CL2020002809A1 (en) 2021-04-30
US20190343968A1 (en) 2019-11-14
BR112020021962A2 (en) 2021-01-26
US20230233711A1 (en) 2023-07-27
TW202003053A (en) 2020-01-16
TW202344691A (en) 2023-11-16
SG11202010533WA (en) 2020-11-27
CA3098674A1 (en) 2019-11-07
US10874750B2 (en) 2020-12-29
US20210162075A1 (en) 2021-06-03
AU2019261982A1 (en) 2020-10-15
PH12020551818A1 (en) 2021-07-26
JP2021521851A (en) 2021-08-30
KR20210005154A (en) 2021-01-13
MX2020011514A (en) 2020-12-09
WO2019213180A1 (en) 2019-11-07
TWI808169B (en) 2023-07-11

Similar Documents

Publication Publication Date Title
CO2020014729A2 (en) Gene therapy constructs and methods for their use
UY37829A (en) INTERLEUCINE MUTEINS 21 AND TREATMENT METHODS
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
MX2024008677A (en) Camptothecin conjugates.
CL2019002626A1 (en) Anti-par2 antibodies and their uses.
PE20200006A1 (en) NEW BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFICALLY BINDING CD40 AND FAP
ECSP19011185A (en) Bispecific antibody-like binding proteins that specifically bind CD3 and CD123
CO2017001023A2 (en) Antibody-Carrier Compositions and Methods for Making and Using Them
PE20190563A1 (en) OPTIMIZED MINI-DISTROPHIN GENES AND EXPRESSION CASSETS AND THEIR USE
AR101953A1 (en) FUSION PROTEINS, RECOMBINANT BACTERIA AND METHODS OF USE OF THE RECOMBINANT BACTERIA
UY35964A (en) HUMAN ANTIBODIES FOR PD? 1
ECSP18096095A (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM
CL2021000909A1 (en) Stabilizing Trem2 Antibodies
MX2020004801A (en) Bispecific fusion polypeptides and methods of use thereof.
MX2020010881A (en) Anti-ror antibody constructs.
UY32812A (en) HIGH AFFINITY HUMAN ANTIBODIES FOR ANGIOPOYETINA -2 HUMANA.
BR112021024463A2 (en) Oligonucleotides and methods of use for the treatment of neurological diseases
CL2021000855A1 (en) Alphavirus-based replicons for the delivery of biotherapies.
EA202191557A1 (en) COMBINED THERAPY WITH RADIOIMMUNOCONJUGATES AND DNA DAMAGE REPAIR INHIBITORS
CO2020013050A2 (en) Human kinureninase enzymes and their uses
BR112022010179A2 (en) YELLOW FEVER ANTI-VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE
AR104484A1 (en) ANTI-PSMA ANTIBODIES AS THERAPEUTIC AGENTS
UY37630A (en) PHARMACEUTICAL COMBINATION, KIT, GUEST CELL THAT PRODUCES IT AND ITS USE IN METHODS FOR CANCER TREATMENT
DOP2015000211A (en) ANTI-CD52 ANTIBODIES
AR121390A1 (en) COMPOSITIONS AND METHODS FOR TREATING NON-AGE RELATED HEARING IMPAIRMENT IN A HUMAN SUBJECT